Baird Maintains Outperform on Ocular Therapeutix, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Colleen Kusy maintains an Outperform rating on Ocular Therapeutix (NASDAQ:OCUL) and raises the price target from $10 to $12.
June 13, 2023 | 4:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst Colleen Kusy maintains an Outperform rating on Ocular Therapeutix and raises the price target from $10 to $12.
The news of Baird maintaining an Outperform rating and raising the price target for Ocular Therapeutix is positive for the company. This indicates that the analyst has a favorable view of the company's prospects and expects the stock price to rise in the short term. As a result, this news is likely to have a positive impact on OCUL's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100